To the Editor In their Brief Report in JAMA Oncology, Gonzalez-Cao et al1 sought to evaluate the safety of durvalumab in HIV-1–infected patients with advanced cancer. The authors cite immune reconstitution inflammatory syndrome (IRIS) as a safety concern for this patient population. Although theoretically conceivable, the occurrence of IRIS when starting checkpoint inhibition in HIV-1–infected patients has thus far been entirely a hypothetical concern. With the DURVAST study results, the authors conclude that treatment with durvalumab is safe.1 Whether their claim extends to all HIV-1–infected patients with cancer is unknown.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dekker TJA. Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer. JAMA Oncol. Published online September 10, 2020. doi:10.1001/jamaoncol.2020.3389
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: